Albumin Modifications as Early Biomarkers of Chronic Liver Diseases

Launched by UNIVERSITY HOSPITAL, LIMOGES · Mar 12, 2024

Keywords

ClinConnect Summary

This clinical trial, called MALAHBAR, is studying how changes in a protein called albumin in the blood can help predict the progression of chronic liver diseases. Chronic liver disease affects millions of people worldwide and can lead to serious complications. Researchers believe that early changes in albumin might indicate liver damage before it becomes severe. By analyzing these changes, the study aims to develop better methods to diagnose and monitor liver disease, which could ultimately help improve treatment and patient outcomes.

To participate in this study, individuals must be at least 18 years old and have some liver damage but not severe liver failure. Participants will undergo blood tests as part of their regular care, and they'll be closely monitored over three years to see how well the albumin changes can predict liver disease progression. It's important to note that certain people, such as those with advanced liver disease or certain health conditions, won't be eligible to join. If you're interested in participating, you'll receive detailed information to help you understand what to expect throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years old
• • With a compensated fibrosis defined by an hepatic elasticity ≥10 kPa measured by FibroScan®
• • Having had blood test at the hospital as part of a consultation or an hospitalisation at the inclusion including usual parameters for the liver disease follow-up
• • Affiliated with or beneficiaries of a social security system
• • Not opposed to participate to the study after being informed
• Exclusion Criteria:
• • Patients suffering from decompensated cirrhosis or with an history of decompensated cirrhosis
• • Patients who received an albumin infusion in the month before the inclusion visit
• • Patients suffering from stage 4 or 5 renal failure (GFR \< 29 ml/min/1,73m²)
• • Patients suffering from cancer
• • Pregnant or breastfeeding women or women of childbearing age without effective contraception (based on declaration)
• • Patients suffering from impairment of mental faculties or a psychiatric disorder which could interfere with the understanding of the study